Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Guerin therapy: Correlation to clinical outcome
Tumor Suppressor Protein p53
Urinary Bladder Neoplasms
In this high-risk population of patients with superficial bladder tumors, patients who have p53 nuclear overexpression in the tumor and stage T1 disease before BCG therapy are at high risk of disease progression. Furthermore, in the group of patients with residual disease after BCG therapy, p53 status is a better predictor of disease progression than post-BCG stage.